Naglie I G, Detsky A S
Division of General Internal Medicine, Geriatric Medicine, and Clinical Epidemiology, Toronto Hospital, Ontario, Canada.
Med Decis Making. 1992 Oct-Dec;12(4):239-49. doi: 10.1177/0272989X9201200401.
The objective of the study was to determine the preferred treatment strategy for elderly patients with chronic nonvalvular atrial fibrillation (CNVAF). A Markov decision-analytic model was used to compare three treatment strategies for CNVAF: 1) warfarin; 2) aspirin; and 3) no treatment. Five-year quality-adjusted life years (QALYs) were calculated for male and female cohorts aged 70 and 75 years. In the baseline analysis (effectiveness of warfarin = 0.70, effectiveness of aspirin = 0.45, utility of warfarin = 0.99, and utility of aspirin = 0.999) the quality-adjusted survival rates for 70-year-old males were 4.03 QALYs on warfarin, 4.02 QALYs on aspirin, and 3.95 QALYs on no treatment. Results were similar for all age and sex cohorts. Sensitivity analyses revealed that the results were very sensitive to the effectiveness of aspirin and the disutility of warfarin. The authors conclude that the optimal strategy for the treatment of CNVAF in elderly patients varies with the disutility assigned to warfarin therapy and the effectiveness value for aspirin therapy.
该研究的目的是确定老年慢性非瓣膜性心房颤动(CNVAF)患者的首选治疗策略。采用马尔可夫决策分析模型比较CNVAF的三种治疗策略:1)华法林;2)阿司匹林;3)不治疗。计算了70岁和75岁男性及女性队列的五年质量调整生命年(QALY)。在基线分析中(华法林有效性=0.70,阿司匹林有效性=0.45,华法林效用=0.99,阿司匹林效用=0.999),70岁男性服用华法林的质量调整生存率为4.03 QALY,服用阿司匹林为4.02 QALY,不治疗为3.95 QALY。所有年龄和性别的队列结果相似。敏感性分析表明,结果对华法林的无效用及阿司匹林的有效性非常敏感。作者得出结论,老年CNVAF患者的最佳治疗策略因华法林治疗的无效用及阿司匹林治疗的有效性值而异。